CN105899211A - 使用cbp/连环蛋白的抑制剂治疗肝纤维化 - Google Patents

使用cbp/连环蛋白的抑制剂治疗肝纤维化 Download PDF

Info

Publication number
CN105899211A
CN105899211A CN201480057194.7A CN201480057194A CN105899211A CN 105899211 A CN105899211 A CN 105899211A CN 201480057194 A CN201480057194 A CN 201480057194A CN 105899211 A CN105899211 A CN 105899211A
Authority
CN
China
Prior art keywords
optionally substituted
triazine
dioxo
methyl
pyrazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480057194.7A
Other languages
English (en)
Chinese (zh)
Inventor
小路弘行
小田上刚直
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN105899211A publication Critical patent/CN105899211A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201480057194.7A 2013-10-18 2014-10-17 使用cbp/连环蛋白的抑制剂治疗肝纤维化 Pending CN105899211A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892606P 2013-10-18 2013-10-18
US61/892606 2013-10-18
PCT/IB2014/002846 WO2015056104A2 (en) 2013-10-18 2014-10-17 Treatment of hepatic fibrosis using an inhibitor of cbp/catenin

Publications (1)

Publication Number Publication Date
CN105899211A true CN105899211A (zh) 2016-08-24

Family

ID=52828810

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480057194.7A Pending CN105899211A (zh) 2013-10-18 2014-10-17 使用cbp/连环蛋白的抑制剂治疗肝纤维化

Country Status (5)

Country Link
US (1) US20160263131A1 (https=)
EP (1) EP3057590B1 (https=)
JP (1) JP6507336B2 (https=)
CN (1) CN105899211A (https=)
WO (1) WO2015056104A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6303112B2 (ja) 2012-12-12 2018-04-04 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 肝線維症の予防または治療剤
CN110156774A (zh) * 2016-07-29 2019-08-23 新波制药有限公司 用于治疗hbv感染的新颖治疗剂
KR20180045213A (ko) * 2016-10-25 2018-05-04 경상대학교산학협력단 Icg-001을 함유하는 섬유증의 예방 또는 치료용 약학 조성물
WO2018167503A1 (en) * 2017-03-15 2018-09-20 Ziylo Limited Macrocyclic compounds
JPWO2020122022A1 (ja) * 2018-12-10 2021-10-28 東京都 肝機能改善剤
BR112022015864A2 (pt) * 2020-02-11 2023-01-17 Ospedale San Raffaele Srl Composto, composição farmacêutica, processo para a síntese de composto, uso de um composto e uso de uma composição
KR20210153908A (ko) * 2020-06-11 2021-12-20 제이더블유중외제약 주식회사 코로나바이러스감염증-19(covid-19) 치료용 조성물
CN113730403A (zh) * 2021-09-26 2021-12-03 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 化合物kya1797k制备抗hbv病毒药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
WO1994003494A1 (en) 1992-08-06 1994-02-17 The Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of reverse turns and peptides containing the same
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6013458A (en) * 1995-10-27 2000-01-11 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US6184223B1 (en) 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7915251B2 (en) * 2005-03-18 2011-03-29 Institute For Chemical Genomics Alpha-helix mimetics and methods relating to the treatment of fibrosis
WO2007056513A1 (en) 2005-11-08 2007-05-18 Institute For Chemical Genomics α-HELIX MIMETICS AND METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS
KR101486490B1 (ko) 2005-11-08 2015-01-27 제이더블유중외제약 주식회사 α-헬릭스 유사체 및 암 줄기세포의 치료에 관한 방법
WO2009148192A1 (en) * 2008-06-06 2009-12-10 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
CN102186853A (zh) 2008-10-14 2011-09-14 株式会社棱镜生物实验室 治疗癌症α-螺旋模拟物
US9040531B2 (en) 2009-05-07 2015-05-26 Prism BioLab Co., Ltd. Alpha helix mimetics and methods relating thereto
US20130274215A1 (en) * 2010-04-08 2013-10-17 Fate Therapeutics, Inc. Pharmaceutical compositions to treat fibrosis
US20140051706A1 (en) * 2011-02-25 2014-02-20 Prism Pharma Co., Ltd. Alpha helix mimetics and methods relating thereto
JP6303112B2 (ja) * 2012-12-12 2018-04-04 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 肝線維症の予防または治療剤

Also Published As

Publication number Publication date
EP3057590B1 (en) 2019-11-27
WO2015056104A3 (en) 2015-06-18
JP6507336B2 (ja) 2019-05-08
EP3057590A4 (en) 2017-06-07
EP3057590A2 (en) 2016-08-24
US20160263131A1 (en) 2016-09-15
JP2016535082A (ja) 2016-11-10
WO2015056104A2 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
JP6507336B2 (ja) Ｃｂｐ／カテニン阻害剤を用いる肝線維症の治療
Mooli et al. Oxidative stress and redox signaling in the pathophysiology of liver diseases
Ryu et al. Dasatinib regulates LPS-induced microglial and astrocytic neuroinflammatory responses by inhibiting AKT/STAT3 signaling
WO2009045397A1 (en) Methods for treating polycystic kidney desease (pkd) or other cyst forming diseases
Guan et al. Dysregulated chemokine signaling in cystic fibrosis lung disease: a potential therapeutic target
JP2010520200A (ja) 特定のマトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤を使用する肝疾患を治療する方法
Li et al. Dexmedetomidine attenuates lung injury in toxic shock rats by inhibiting inflammation and autophagy
Lei et al. Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway
Niina et al. A sustained prostacyclin analog, ONO-1301, attenuates pancreatic fibrosis in experimental chronic pancreatitis induced by dibutyltin dichloride in rats
Benitez et al. Cortistatin regulates fibrosis and myofibroblast activation in experimental hepatotoxic‐and cholestatic‐induced liver injury
Kai-Lan et al. Pretreatment with erythropoietin attenuates intestinal ischemia reperfusion injury by further promoting PI3K/Akt signaling activation
Cheon et al. Niclosamide suppresses RANKL-induced osteoclastogenesis and prevents LPS-induced bone loss
CN102018689A (zh) 姜黄素的一种新用途
JP2021527669A (ja) 線維症の軽減又は治療のための組成物及び方法
JP2015534942A (ja) Ｃｂｐ／カテニン阻害剤を用いる過剰増殖性及び前がん性皮膚病の治療
WO2019103984A1 (en) Compositions including fatp1, fatp3, fatp4, fatp5, and/or fatp6 inhibitors and uses thereof
WO2017005886A1 (en) Reverted stellate cells and uses thereof
US20160166577A1 (en) Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin
JP2006504769A (ja) 病理学的プロセスに関する遺伝子発現を制御するためのキナゾリノン組成物
EP4144350B1 (en) Treatment or prevention of vascular malformation
KR102715760B1 (ko) 카테콜아민/adrb2 매개 간질환 치료제 스크리닝 방법
US9138466B2 (en) Factor H for transplantation
Wang et al. Effects of propofol and etomidate pretreatment on glucocorticoid receptor expression following induction of sepsis in rats
Li et al. USP19 alleviates LPS-induced acute lung injury via inhibiting TAK1 activation
KR20260019721A (ko) Nsc-38270을 유효성분으로 포함하는 간암 전이 예방 및 억제용 약제학적 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160824

WD01 Invention patent application deemed withdrawn after publication